Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f
Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2024, ended March 31, 2024. Commenting on the fiscal year results (changes shown vs. fiscal 2023), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Although the year was filled with challenges, our team effectively managed spending, production and inventory to conclude the year with only slightly increased debt of $209,000. As we look forward to this next year, and the increasing interest we are currently seeing in our products along with new product offe
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2024, ended December 31, 2023. Commenting on the third quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The macroeconomic environment led to lower sales across the portfolio on a year-to-date basis, being driven particularly by Spirulina bulk sales. Industry data shows consumers are not pulling back from dietary supplements, but they have begun trading down to private label brands to save on c
Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f
Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2024, ended March 31, 2024. Commenting on the fiscal year results (changes shown vs. fiscal 2023), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Although the year was filled with challenges, our team effectively managed spending, production and inventory to conclude the year with only slightly increased debt of $209,000. As we look forward to this next year, and the increasing interest we are currently seeing in our products along with new product offe
The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin® per serving – 6000 times the antioxidant power of Vitamin C – with science-backed, multifunctional benefits and a 40-year legacy of farm-direct transparency and traceability. Nutrex-Hawaii, Inc., a wholly owned subsidiary of Cyanotech Corporation, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving. At the forefront of natural microalgae innovation, Nutrex-Hawaii addresses the evolving preferences of today's discerning consumers with its new gummies, offering a ho
8-K - CYANOTECH CORP (0000768408) (Filer)
8-K - CYANOTECH CORP (0000768408) (Filer)
10-Q - CYANOTECH CORP (0000768408) (Filer)
The Dow Jones index closed lower by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Retractable Technologies The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw bought a total of 12,710 shares at an average price of $1.13. To acquire these shares, it cost around $14,352. What's Happening:
The Dow Jones index closed higher by more than 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Alpha Teknova The Trade: Alpha Teknova, Inc. (NASDAQ:TKNO) 10% owner Telegraph Hill Partners Management Company, LLC bought a total of 12,096,773 shares at an average price of $1.24. To acquire these shares, it cost around $15 million. The co
The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. ARCA biopharma The Trade: ARCA biopharma, Inc. (NASDAQ:ABIO) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd bought a total of 408,777 shares at an average price of $3.49. To acquire these shares, it cost around $1.4 million. W
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)